MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-21-2025
Quest Diagnostics Incorporated Interest Expense 2011-2026 | DGX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Quest Diagnostics Incorporated
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 30 M | 20 M | -55 M | 152 M | 166 M | 180 M | 169 M | 153 M | 144 M | 154 M | 167 M | 8 M | 6 M | 173 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 180 M | -55 M | 105 M |
Quarterly Interest Expense Quest Diagnostics Incorporated
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8 M | 13 M | -3 M | 15 M | 3 M | 9 M | -3 M | 39 M | 37 M | - | 37 M | 38 M | 37 M | - | 38 M | 38 M | 38 M | - | 42 M | 42 M | 42 M | - | 45 M | 46 M | 45 M | - | 42 M | 43 M | 41 M | - | 39 M | 38 M | 37 M | - | 37 M | 35 M | 36 M | - | 35 M | 37 M | 45 M | - | 42 M | 42 M | 40 M | - | 3 M | - | 4 M | - | 41.7 M | 42.6 M | 43 M | - | 44.1 M | 47.2 M | 38.3 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 47.2 M | -3 M | 33.2 M |
Interest Expense of other stocks in the Diagnostics research industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Akumin
AKU
|
118 M | - | -17.87 % | $ 25.9 M |  Canada |
|
Centogene N.V.
CNTG
|
8.42 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Accelerate Diagnostics
AXDX
|
235 K | - | -61.36 % | $ 2.46 M |  USA |
 |
Biocept
BIOC
|
316 K | - | -13.05 % | $ 7.29 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
1.54 M | $ 20.15 | -2.3 % | $ 217 M |  China |
 |
Co-Diagnostics
CODX
|
106 K | $ 5.06 | 2699.11 % | $ 148 M | USA |
 |
Castle Biosciences
CSTL
|
1 K | $ 38.9 | -1.04 % | $ 1.08 B | USA |
 |
Chembio Diagnostics
CEMI
|
2.94 K | - | 0.22 % | $ 16.8 M | USA |
 |
Danaher Corporation
DHR
|
-56 M | $ 228.92 | -0.78 % | $ 167 B | USA |
 |
DexCom
DXCM
|
20.3 M | $ 66.37 | -1.03 % | $ 25.6 B | USA |
 |
BioNano Genomics
BNGO
|
-10.1 M | $ 1.53 | 2.0 % | $ 1.94 M | USA |
 |
Enzo Biochem
ENZ
|
494 K | - | -8.98 % | $ 14.8 K | USA |
 |
DermTech
DMTK
|
-355 K | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
-31 K | $ 11.38 | 6.36 % | $ 323 M |  Israel |
 |
Exact Sciences Corporation
EXAS
|
18.6 M | $ 101.56 | -0.33 % | $ 18.8 B | USA |
 |
IQVIA Holdings
IQV
|
670 M | $ 225.41 | -0.99 % | $ 40.9 B | USA |
 |
Fulgent Genetics
FLGT
|
561 K | $ 26.27 | -0.83 % | $ 794 M | USA |
 |
Global Cord Blood Corporation
CO
|
6.27 M | - | - | $ 399 M | China |
 |
Genetic Technologies Limited
GENE
|
15.2 K | - | - | $ 7.1 B |  Australia |
 |
Heska Corporation
HSKA
|
4.19 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
857 K | - | -20.0 % | $ 1.06 M | USA |
 |
CareDx, Inc
CDNA
|
1.34 M | $ 18.84 | -1.21 % | $ 1.01 B | USA |
 |
Celcuity
CELC
|
2.11 M | $ 99.74 | -0.18 % | $ 3.93 B | USA |
 |
Anixa Biosciences
ANIX
|
500 K | $ 3.12 | - | $ 99.5 K | USA |
 |
Myriad Genetics
MYGN
|
1.1 M | $ 6.15 | -0.32 % | $ 557 M | USA |
 |
ENDRA Life Sciences
NDRA
|
-691 K | $ 4.53 | -4.83 % | $ 2.43 M | USA |
 |
NeoGenomics
NEO
|
-379 K | $ 11.76 | -3.84 % | $ 1.49 B | USA |
 |
Guardant Health
GH
|
-42.6 M | $ 102.14 | 1.53 % | $ 12.5 B | USA |
 |
National Research Corporation
NRC
|
862 K | $ 18.77 | 0.64 % | $ 461 M | USA |
 |
OPKO Health
OPK
|
207 M | $ 1.26 | -3.08 % | $ 874 M | USA |
 |
Aspira Women's Health
AWH
|
106 K | - | -6.19 % | $ 10.5 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
288 M | $ 27.08 | -1.13 % | $ 20 B |  Niderland |
 |
Precipio
PRPO
|
-1 K | $ 22.98 | -1.84 % | $ 29.8 M | USA |
 |
Personalis
PSNL
|
24 K | $ 7.96 | -0.13 % | $ 472 M | USA |
 |
Motus GI Holdings
MOTS
|
211 | - | -34.28 % | $ 263 K | Israel |
 |
Soleno Therapeutics
SLNO
|
110 K | $ 46.3 | 0.02 % | $ 1.86 B | USA |
 |
Illumina
ILMN
|
-292 M | $ 131.16 | -1.2 % | $ 20.9 B | USA |
 |
Charles River Laboratories International
CRL
|
-16.5 M | $ 199.48 | -1.24 % | $ 10.2 B | USA |
|
Biodesix
BDSX
|
8.26 M | $ 6.8 | 1.19 % | $ 882 M | USA |
 |
Laboratory Corporation of America Holdings
LH
|
208 M | $ 250.88 | -0.87 % | $ 21 B | USA |
 |
ICON Public Limited Company
ICLR
|
337 M | $ 182.22 | -0.43 % | $ 15 B |  Irlanda |
 |
IDEXX Laboratories
IDXX
|
29.8 M | $ 676.53 | -0.85 % | $ 55.8 B | USA |
 |
Lantheus Holdings
LNTH
|
37.2 M | $ 66.55 | -0.91 % | $ 4.61 B | USA |
 |
Mettler-Toledo International
MTD
|
74.6 M | $ 1 394.19 | -1.42 % | $ 29.6 B |  Schweiz |